• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    施

    施普林格·自然

    Springer Nature Inc.
    企业
    1,688论文总数
    2.8万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1688)

    年份
    起
    –
    止
    排序
    1Maintain Euthymia and Prevent Mood Episodes in Pregnant and Postpartum Women with Bipolar Disorder
    Kimberley Chen,Connie Kang

    The pharmacological management of bipolar disorder (BD) in pregnancy and postpartum is complex and requires careful consideration of both maternal and foetal/neonatal health. The goal of therapy is to achieve euthymia and prevent future mood episodes whilst minimising risks of adverse foetal/neonatal outcomes. Treatment options during pregnancy and the postpartum period include lithium and lamotrigine as mood stabilisers. Antipsychotics also play a key role in the treatment of acute mania and maintenance treatment of BD. Antidepressants can be used as adjunctive therapy for bipolar depression in patients who are resistant to alternative medicines. Sleep preservation is also essential in preventing bipolar episode-relapse during pregnancy and especially during the postpartum period.

    2026Drugs & Therapy Perspectives(2026)引用:31
    引用
    AI阅读
    加入学术空间
    2Sonrotoclax: First Approval.
    Hannah A. Blair

    Sonrotoclax (Baiyueda®), a small-molecule B-cell lymphoma-2 (BCL-2) inhibitor, is being developed by BeOne Medicines for the treatment of various B-cell malignancies. On 6 January 2026, sonrotoclax received conditional approval in China for adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL) who have previously received at least one systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor, and adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two systemic therapies, including a BTK inhibitor. This article summarizes the milestones in the development of sonrotoclax leading to this first approval for the second-line treatment of relapsed/refractory CLL/SLL and MCL.

    2026Drugs(2026)引用:13
    引用
    AI阅读
    加入学术空间
    3Recaticimab in Primary Hypercholesterolaemia and Mixed Dyslipidaemia: a Profile of Its Use
    Thomas B. Burgess, Hannah A. Blair
    2026Drugs & Therapy Perspectives(2026)引用:12
    引用
    AI阅读
    加入学术空间
    4Narsoplimab: First Approval
    Matt Shirley

    Narsoplimab (narsoplimab-wuug; YARTEMLEA®) is a recombinant human immunoglobulin G4 monoclonal antibody targeted against mannan-binding lectin-associated serine protease 2 (MASP-2) being developed by Omeros Corporation initially for the treatment of haematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TA-TMA). MASP-2 inhibition by narsoplimab is thought to provide benefit in patients with TA-TMA by decreasing or preventing lectin complement pathway-mediated cellular injury. In December 2025, narsoplimab received its first approval, in the USA, for the treatment of adult and paediatric patients aged ≥ 2 years with TA-TMA. Additionally, a Marketing Authorisation Application for narsoplimab for the treatment of TA-TMA is currently under regulatory review in the EU. This article summarises the milestones in the development of narsoplimab leading to this first approval for TA-TMA.

    2026Drugs(2026)引用:9
    引用
    AI阅读
    加入学术空间
    5Pixavir Marboxil: First Approval
    Connie Kang

    Pixavir marboxil (Yilikang®; ®) is an oral cap-snatching endonuclease inhibitor being developed by TaiGen Biotechnology for the treatment of influenza virus infections. Pixavir marboxil recently received approval in China for the treatment of uncomplicated influenza A and B in previously healthy adults and adolescents aged ≥ 12 years. This article summarizes the milestones in the development of pixavir marboxil leading to this first approval for uncomplicated influenza A and B infections.

    2026Drugs(2026)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1688 篇论文

    合作机构(100)

    Deutsche Nationalbibliothek合作论文 20
    新加坡国立大学合作论文 10
    哥伦比亚大学合作论文 7
    牛津大学合作论文 5
    普林斯顿大学合作论文 5
    Altrecht GGZ合作论文 5
    Christophorus Kliniken合作论文 5
    开放大学合作论文 5
    鲁尔波鸿大学合作论文 4
    科布伦茨 - 兰道大学合作论文 4

    机构统计